Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 12/20 | 0.48 |
| ▸ | LIPG | Q9Y5X9 | 12/20 | 0.48 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.38 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA9 | Q16790 | 2/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA3 | P07451 | 1/20 | 0.35 |
| ▸ | CA4 | P22748 | 1/20 | 0.35 |
| ▸ | CA6 | P23280 | 1/20 | 0.35 |
| ▸ | CA5A | P35218 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.35 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1284338 | 0.81 | LPL (0.42) | LPLLIPGFFAR1DGAT1CA1 | |
| SCHEMBL28990423 | 0.79 | LPL (0.41) | LPLLIPGFFAR1DGAT1CA1 | |
| SCHEMBL189971 | 0.79 | LPL (0.41) | LPLLIPGFFAR1DGAT1AAK1 | |
| SCHEMBL759177 | 0.79 | LPL (0.41) | LPLLIPGFFAR1DGAT1CA1 | |
| SCHEMBL11984114 | 0.79 | LPL (0.41) | LPLLIPGFFAR1DGAT1CA1 | |
| SCHEMBL20315296 | 0.79 | FFAR1 (0.42) | LPLLIPGFFAR1DGAT1CA1 | |
| SCHEMBL5062546 | 0.79 | LPL (0.41) | LPLLIPGFFAR1DGAT1AAK1 | |
| SCHEMBL16634904 | 0.79 | LPL (0.41) | LPLLIPGFFAR1DGAT1AAK1 | |
| SCHEMBL20162735 | 0.79 | AAK1 (0.42) | LPLLIPGFFAR1DGAT1AAK1 | |
| SCHEMBL29505265 | 0.79 | LPL (0.53) | LPLLIPGFFAR1DGAT1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260124205-A1 | MODULATORS OF BETA CATENIN AND USES THEREOF | DEWPOINT THERAPEUTICS INC (US) | 2026-05-07 | — | — | US | disclosed |
| WO-2026090104-A1 | MODULATORS OF BETA CATENIN AND USES THEREOF | DEWPOINT THERAPEUTICS, INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| EP-4722206-A1 | BENZO(HETERO)CYCLOALKYL COMPOUNDS FOR ANDROGEN RECEPTOR-DEPENDENT DISEASES | Haihe Biopharma Co., Ltd. (CN) | 2026-04-08 | — | — | EP | disclosed |
| EP-4698544-A1 | COMPOUNDS AND USES THEREOF | Foghorn Therapeutics Inc. (US) | 2026-02-25 | — | — | EP | disclosed |
| US-20250170248-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-05-29 | — | — | US | disclosed |
| US-20250101012-A1 | HETEROCYCLE SUBSTITUTED PYRIDINE DERIVATIVE ANTIFUNGAL AGENTS | BASILEA PHARMACEUTICA INTERNATIONAL AG, ALLSCHWIL (CH) | 2025-03-27 | — | — | US | disclosed |
| WO-2024245408-A1 | BENZO(HETERO)CYCLOALKYL COMPOUNDS FOR ANDROGEN RECEPTOR-DEPENDENT DISEASES | 上海海和药物研究开发股份有限公司 | 2024-12-05 | — | — | WO | disclosed |
| EP-4471028-A1 | HYDRAZINO GROUP-CONTAINING COMPOUND | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2024-12-04 | — | — | EP | disclosed |
| US-12139479-B2 | Heterocycle substituted pyridine derivative antifungal agents | BASILEA PHARMACEUTICA INTERNATIONAL AG, ALLSCHWIL (CH) | 2024-11-12 | — | — | US | disclosed |
| WO-2024220946-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2024-10-24 | — | — | WO | disclosed |
| US-10172845-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-10144734-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2018-12-04 | — | — | US | disclosed |
| US-10137124-B2 | Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2018-11-27 | — | — | US | disclosed |
| US-10112942-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2018-10-30 | — | — | US | disclosed |
| US-20180148445-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-31 | — | — | US | disclosed |
| US-20180133213-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-17 | — | — | US | disclosed |
| US-20180134703-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-17 | — | — | US | disclosed |
| US-20180133207-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-17 | — | — | US | disclosed |
| US-20180133200-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-17 | — | — | US | disclosed |
| US-20180134702-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250101012-A1 | HETEROCYCLE SUBSTITUTED PYRIDINE DERIVATIVE ANTIFUNGAL AGENTS | ERG28, DPM1, CYP51A1 | LPL 4735/4885LIPG 4496/4885FFAR1 3847/4885 |
| US-20180134702-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, ROR1, BRAF | LPL 4820/4885LIPG 4659/4885FFAR1 3002/4885 |
| US-20180148445-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, RAF1 | LPL 4797/4885LIPG 4689/4885FFAR1 3257/4885 |
| US-20250170248-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCA2, SMARCC2 | LPL 2419/4885LIPG 2521/4885FFAR1 4533/4885 |
| US-20260124205-A1 | MODULATORS OF BETA CATENIN AND USES THEREOF | CTNNB1, CTNNA1, CTNND1 | LPL 1357/4885LIPG 2077/4885FFAR1 2397/4885 |
| US-12139479-B2 | Heterocycle substituted pyridine derivative antifungal agents | ERG28, DPM1, CYP51A1 | LPL 4735/4885LIPG 4496/4885FFAR1 3847/4885 |
| US-10144734-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | RET, BRAF, RAF1 | LPL 4797/4885LIPG 4689/4885FFAR1 3257/4885 |
| US-10112942-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | RET, ROR1, BRAF | LPL 4820/4885LIPG 4659/4885FFAR1 3002/4885 |
| US-20180133200-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, ROR1, BRAF | LPL 4820/4885LIPG 4659/4885FFAR1 3002/4885 |
| US-10172845-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | RET, BRAF, RAF1 | LPL 4797/4885LIPG 4689/4885FFAR1 3257/4885 |
| US-20180133207-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, RAF1 | LPL 4797/4885LIPG 4689/4885FFAR1 3257/4885 |
| US-10137124-B2 | Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors | RET, ROR1, BRAF | LPL 4820/4885LIPG 4659/4885FFAR1 3002/4885 |
| US-20180134703-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, RAF1 | LPL 4797/4885LIPG 4689/4885FFAR1 3257/4885 |
| US-20180133213-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, ROR1, BRAF | LPL 4820/4885LIPG 4659/4885FFAR1 3002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.